Fusion Pharmaceuticals Inc (DELISTED) (FUSN:DL)
21.55
0.00 (0.00%)
USD |
NASDAQ |
Jun 04, 16:00
Fusion Pharmaceuticals Research and Development Expense (TTM): 75.54M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 75.54M |
| December 31, 2023 | 70.10M |
| September 30, 2023 | 67.06M |
| June 30, 2023 | 69.03M |
| March 31, 2023 | 62.11M |
| December 31, 2022 | 58.90M |
| September 30, 2022 | 53.10M |
| June 30, 2022 | 49.23M |
| March 31, 2022 | 58.30M |
| Date | Value |
|---|---|
| December 31, 2021 | 56.36M |
| September 30, 2021 | 49.51M |
| June 30, 2021 | 41.35M |
| March 31, 2021 | 23.53M |
| December 31, 2020 | 17.19M |
| September 30, 2020 | 15.65M |
| June 30, 2020 | 13.36M |
| March 31, 2020 | 12.17M |
| December 31, 2019 | 10.63M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
10.63M
Minimum
Dec 2019
75.54M
Maximum
Mar 2024
44.62M
Average
51.30M
Median
Research and Development Expense (TTM) Benchmarks
| AstraZeneca PLC | 11.11B |
| Landos Biopharma Inc (DELISTED) | 11.82M |
| Acasti Pharma Inc | 4.683M |
| Aurinia Pharmaceuticals Inc | 49.64M |
| Edesa Biotech Inc | 3.860M |